Safety, Tolerability and Antitumour Activity of Lorlatinib in Patients with ALK-Driven Refractory or Relapsed Neuroblastoma
Findings from the NANT2015-02 study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1533 results
EMA Recommends Granting a Paediatric-Use Marketing Authorisation for Sodium Thiosulfate
It is indicated for the prevention of ototoxicity induced by cisplatin in paediatric patients with localised, non-metastatic, solid tumours
Combination of Enzalutamide Plus Abiraterone Acetate and Prednisone Offers No Clinical Advantage Over Enzalutamide Alone in First-Line Treatment of mCRPC
Findings from the Alliance A031201 study
Isolated Hepatic Perfusion with Melphalan Improves Response Rate and PFS in Previously Untreated Patients with Isolated Liver Metastases from Uveal Melanoma
Findings from the SCANDIUM study
EMA Recommends Extension of Therapeutic Indications for Lisocabtagene Maraleucel
New indication concerns treatment of adult patients with DLBCL, HGBCL, PMBCL and FL3B, who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy
pCR Associated with Improved Survival Outcomes in Patients with Soft Tissue Sarcoma Who Received Neoadjuvant Chemoradiotherapy or Radiotherapy
Findings from ancillary analysis of RTOG 9514 and 0630 studies
Helicobacter Pylori Infection Modifies the Risk of Gastric Cancer Associated with Germline Pathogenic Variants in Homologous Recombination Genes
Findings from an analysis of two independent study cohorts
Adding Pembrolizumab to Standard Chemotherapy, Followed by Pembrolizumab Maintenance, Results in Longer PFS in Patients with Advanced or Recurrent Endometrial Cancer
Findings from the NRG-GY018 study
Apalutamide Plus ADT Demonstrates a Rapid, Deep, and Durable PSA Decline Associated with Improved Clinical Outcomes in Patients with mCSPC
Findings from a post hoc exploratory analysis of the TITAN study
FDA Grants Accelerated Approval to Retifanlimab-dlwr for Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma
Evidence for efficacy is based on the results from the PODIUM-201 study
Prognostic Role of Plasmatic BRAF Allele Fraction for Survival in Patients with BRAF V600E-mutated mCRC Treated with BRAF Inhibitor-Based Combination Therapies
Droplet digital PCR detects BRAF allele fraction in ctDNA with high reproducibility and sensitivity, offering an alternative to NGS
FDA Approves Dabrafenib with Trametinib for Paediatric Patients with Low-Grade Glioma with a BRAF V600E Mutation
Evidence for efficacy is based on the results from the Study CDRB436G2201